Novavax, Inc. (NVAX.MX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John Charles Jacobs M.B.A. | President, CEO & Director | 30.39M | -- | 1967 |
| Mr. John Joseph Trizzino B.S., M.B.A. | President & COO | 16.8M | -- | 1960 |
| Mr. James Patrick Kelly C.F.A. | Executive VP, CFO & Treasurer | 17.26M | -- | 1966 |
| Mr. Mark J. Casey | Executive VP, Chief Legal Officer & Corporate Secretary | 19.55M | -- | 1963 |
| Ms. Elaine O'Hara | Executive VP & Chief Strategy Officer | 19.43M | -- | 1968 |
| Mr. Richard P. Crowley | Executive VP & COO | -- | -- | 1957 |
| Mr. Troy Morgan Esq., J.D. | Senior VP, Deputy General Counsel & Chief Compliance Officer | -- | -- | 1971 |
| Ms. Erika S. Trahan | Associate Director of Investor & Public Relations | -- | -- | -- |
| Mr. Ian J. Watkins | Executive VP & Chief Human Resources Officer | -- | -- | 1963 |
| Ms. Silvia Taylor M.B.A. | Executive VP and Chief Corporate Affairs & Advocacy Officer | -- | -- | -- |
Novavax, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 952
Description
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Corporate Governance
Upcoming Events
May 8, 2025 at 12:30 PM UTC
Novavax, Inc. Earnings Date
Recent Events
Recent Events Information Not Available